Douxfils J, Michel S, Beauloye C, Goethals M, Hainaut P, Heidbuchel H, Hermans C, Ickx B, Jochmans K, Mottes S, Mullier F, Peeters A, Scavée C, Sinnaeve P, Sprynger M, Thijs V, Vandenbroeck C, Vandermeulen E, Verhamme P, Dogné JM. [Rivaroxaban: Xarelto--recommendations for pharmacists].
J Pharm Belg 2013:28-36. [PMID:
23638610]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Rivaroxaban is one of the new oral anticoagulants (NOACs). It has many potential advantages in comparison with Vitamin K Antagonists (VKA). It has a predictable anticoagulant effect and does not theoretically require biological monitoring. It is also characterized by less food and drug interactions. However, due to major risks associated with over- and under-dosage, its optimal use in patients should be carefully followed by health care professionals. The aim of this article is to provide recommendations for pharmacists on the practical use of Xarelto in its different approved indications. This document is adapted from the practical user guide of rivaroxaban which was developed by an independent group of Belgian experts in the field of thrombosis and haemostasis.
Collapse